Nov 25, 2019 / 02:00PM GMT
Operator
Good morning, ladies and gentlemen. And welcome to Axsome Therapeutics Conference Call and Webcast. (Operator Instructions) As a reminder, today's conference call is being recorded.
I would now like to turn the conference over to your host, Mark Jacobson, Senior Vice President of Operations at Axsome Therapeutics. Please go ahead.
Mark Jacobson - Axsome Therapeutics, Inc. - SVP of Operations & Secretary
Thank you, operator. Good morning, and thank you all for joining us on today's conference call, focusing on AXS-07 and the unmet needs in the acute treatment of migraine.
During today's call, we will be making certain forward-looking statements. These statements may include statements regarding, among other things, the efficacy, safety, and intended utilization of our product candidates, our clinical and nonclinical plans, our plans to present or report additional data, the anticipated conduct and the source of future clinical trials, regulatory plans, future research and development, and possible intended utilization of cash and
Axsome Therapeutics Inc Investor R&D Call with Migraine Key Opinion Leaders (KOLs) Focusing on AXS-07 Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot